Clinical Trials Browser

Recruiting × talazoparib × Breast × Clear all

NCT04550494 2026-03-19

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 2 Recruiting

Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Phase 2 Recruiting

Advanced Breast Cancer

NCT06193525 2025-02-28

FUTURE

Phase 2 Recruiting

Breast Neoplasms

NCT04819243 2025-01-03

Young-PALETTA

Phase 2 Recruiting

Premenopausal HR+/HER2- Metastatic Breast Cancer